Tenderwize
Retour à la recherche

Open-house discount agreement for Urapidil

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Dec 03, 2027 · 461 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Urapidil, ATC C02CA06

52/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

52 / 100

Complexité

58 / 100

Facteurs de risque

Incorrect submission channel is explicitly disallowed; the buyer says documents must be submitted via the DTVP communic...

The monthly accession mechanism depends on receipt by the 3rd of the month, and paper originals must arrive by the 10th...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house discount agreements for the medicinal product Urapidil, ATC C02CA06.
  • Supply of pharmaceutical products under identical, pre-set contract terms.
Afficher le résumé complet

This is an open-house supply arrangement for pharmaceutical discount agreements on Urapidil (ATC C02CA06) led by AOK Bayern. It is not a competitive award procedure in the usual sense: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement may join on identical, non-negotiable terms. The contract period runs from 2026-02-01 to 2028-01-31, with contract entry possible at any time until 2027-12-03. Submission is via DTVP electronic communication area with a qualified electronic signature, or by paper originals in duplicate; documents not in German must be submitted with a German translation. No contract value is provided.

Risques

Incorrect submission channel is explicitly disallowed; the buyer says documents must be submitted via the DTVP communic...

The monthly accession mechanism depends on receipt by the 3rd of the month, and paper originals must arrive by the 10th...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The contract and the annex 'Festlegung der vertragsgegenständlichen Arzneimittel' must be completed and signed.

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit) must be submitted.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house discount agreement for Urapidil

Open-house pharmaceutical discount agreement for the active substance Urapidil (ATC C02CA06). The lot is described as a supply arrangement for pharmaceutical products. The buyer states that the contract is non-exclusive, identical for all eligible companies, and not individually negotiable. Performance is in Germany, specifically the Bavaria region (DE212).

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jan 2026 - Jan 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Dec 03, 2027

Détails de la procédure

Date de publication
14 Dec 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
831448-2025

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30